Entities / Company
Bristol-Myers Squibb.
American pharmaceutical company
- Reports this week
- 7
- Active events
- 6
- Connections
- 530
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Bristol-Myers Squibb and Özlem Türeci presented late-stage oncology pipeline data and joint development activity in Mainz.Some support1 report
-
Companies are pouring billions into protein degraders, a drug class that has received FDA approval and is being discussed by ASCO.Some support1 report
-
UICC was registered in Geneva on October 1, 2026, involving Bristol-Myers Squibb.Some support1 report
-
Canadian investors can access U.S. companies, including Bristol-Myers Squibb, via Canadian Deposit Receipts (CDRs).Some support1 report
-
Texas AG Ken Paxton sued pharmaceutical companies Sanofi and Bristol-Myers Squibb over alleged drug concealment.Some support1 report
-
CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.Well supported6 reports1 development inside
Earlier this month
-
Bristol-Myers Squibb and Novo Nordisk are noted as competitors in the healthcare sector.Some support1 report
-
A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.Some support4 reports1 development inside
-
Major pharmaceutical companies are competing for investment capital.Some support1 report
-
GSK and Bristol-Myers Squibb are funding research and development for dementia treatments.Some support4 reports
-
Companies across various sectors are actively seeking advanced solutions to enhance their cyber resilience capabilities.Some support1 report
-
Jay Korada held senior analytics roles at both AbbVie and Bristol-Myers Squibb.Some support1 report
-
Bristol-Myers Squibb's price target was cut by Cantor Fitzgerald following clinical setbacks.Some support4 reports
-
Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.Well supported3 reports1 development inside
-
Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Some support1 report
-
FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Some support1 report
-
Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.Some support1 report
-
Bristol Myers Squibb filed with the SEC on May 28, 2026, regarding increased institutional ownership and share purchases.Well supported3 reports
-
Market competition observed in the large-cap healthcare sector involving Bristol-Myers Squibb and Orion OYJ.Some support1 report
-
MarketBeat reported consensus analyst targets and compared financial health for Bristol-Myers Squibb and Shionogi & Co., Ltd.Some support1 report
-
Bristol-Myers Squibb holds exclusive commercial rights in Japan after the FDA accepted Zenas's Biologics License Application.Some support1 report
-
Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.Some support1 report1 development inside
-
AbbVie, AstraZeneca, and Bristol-Myers Squibb collaborated on the AISB Bind AI initiative.Some support2 reports
-
ENCell secured a U.S. patent involving the work of the Samsung Life Public Welfare Foundation, which is connected to Bristol-Myers Squibb.Some support1 report
One to three months ago
-
The Israel National Biotech Innovation Center (INBI) is established as a national center of excellence and a founding partner to various academic and corporate institutions.Some support1 report
-
Robert Plenge holds various appointments, including Chief Research Officer at Bristol-Myers Squibb, and serves on the boards of BioMarin Pharmaceutical and the PhRMA Foundation.Some support1 report
-
Manufacturers Life Insurance Company reduced its share position in Bristol-Myers Squibb.Some support1 report
-
The FDA approved Zenbexus oral therapy for multiple myeloma, coinciding with disclosures regarding insider buying and selling transactions.Some support2 reports1 development inside
-
Insider sale disclosed in SEC filing involving Bristol-Myers Squibb.Some support1 report
-
Pfizer is jointly marketing the drug Eliquis.Some support2 reports
-
Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.Some support3 reports1 development inside
-
Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.Some support2 reports
-
Major healthcare companies like BMS, J&J, and EL are facing market pressures, including biosimilar erosion, while maintaining strong sector positions.Some support1 report1 development inside
-
Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.Some support1 report
-
Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.Some support2 reports
-
Bristol-Myers Squibb announced a $2.3 billion investment in Houston, and Brownsville is slated to receive a new oil refinery.Some support1 report1 development inside
-
Pfizer is based in New York and Bristol-Myers Squibb is based in Princeton, New Jersey.Some support1 report
-
Leerink and Stifel analysts commented on efficacy data following the separation of Myqorzo from the Camzyos market.Some support1 report
-
Joe Bolger is employed by Bristol-Myers Squibb as a sales representative.Some support2 reports
-
The FDA received information on June 27, 2025, regarding regulatory approval to streamline patient monitoring for a product involving Bristol-Myers Squibb.Some support2 reports
-
Negotiated prices are impacting market access and revenue for major pharmaceutical companies like Pfizer, UCB, Bristol-Myers Squibb, and Novartis.Some support1 report
-
Corporate news includes the acquisition of Vidya Therapeutics by Processa Pharmaceuticals, the $7.2 billion acquisition of Receptos by Celgene, and updates regarding Gujrathi's professional history with BMS.Some support1 report
-
RayzeBio, acquired by Bristol-Myers Squibb, plans a $173 million investment and new facility in Boone County, Indiana.Some support6 reports
-
Analysts raised price targets on Bristol-Myers Squibb shares.Some support1 report
-
Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.Some support1 report
-
Bristol-Myers Squibb filed Form 13F with the Securities and Exchange Commission on August 25, 2026.Some support1 report
-
Roche, Novo Nordisk, and Bristol-Myers Squibb are evaluating new drug candidates for Parkinson's, ATTR amyloidosis, and Alzheimer's diseases.Some support1 report1 development inside
-
Bristol-Myers Squibb has taken ownership of Celgene's drug.Some support2 reports
-
Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.Well supported32 reports3 developments inside
-
Bristol-Myers Squibb and AstraZeneca announced a collaboration on advanced cancer drug development.Some support1 report
-
Norges Bank bought shares in Bristol-Myers Squibb (BMY), while TD Cowen and Raymond James Financial started coverage, and Truist Financial reiterated buy ratings.Some support2 reports
-
Bristol-Myers Squibb and others demand policy changes regarding labor and wages from the central government.Some support1 report
-
Vanguard ETF holds major positions in companies including Bristol-Myers Squibb, General Motors, AT&T, Salesforce, EOG Resources, Intuit, and Pfizer.Some support1 report
-
Bristol-Myers Squibb is establishing a new manufacturing campus in the Houston region, supported by a TEF grant and favorable business climate.Well supported6 reports
-
A pilot program involving pharmacies in Alabama and Missouri is underway, with Bristol-Myers Squibb personnel involved.Some support2 reports
-
Nvidia, Eli Lilly, Bristol-Myers Squibb, and Hoffmann-La Roche announced a partnership to build a hybrid-cloud AI factory and powerful AI infrastructure.Some support1 report
-
AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.Some support2 reports
-
Arcus Biosciences established a collaboration with Bristol-Myers Squibb and discussed study plans with the FDA on August 1, 2026.Some support1 report
-
Halozyme tracks patient usage of OCREVUS ZUNOVO and monitors Opdivo Qvantig sales and conversion rates.Some support1 report
-
Talks are underway regarding a potential $400bn mega-merger involving Pfizer, AstraZeneca, and Bristol-Myers Squibb.Well supported3 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Bristol-Myers Squibb
Events traced to Bristol-Myers Squibb, step by step, newest first- Houston's budget gap may affect Bristol-Myers Squibb's investment plansHouston's budget gap may introduce uncertainty for Bristol-Myers SquibbPossible
- I-10 infrastructure changes may disrupt Bristol-Myers Squibb's supply chainBristol-Myers Squibb may face supply chain delays due to I-10 infrastructure changesPossible
- BioNTech executive departures may jeopardize partnership with Bristol-Myers SquibbBioNTech executive departures may jeopardize partnership with Bristol-Myers SquibbPossible
Around Bristol-Myers Squibb this week
News at the entities that move Bristol-Myers Squibb most-
AstraZeneca TransactionalAstraZeneca plans a $2B facility in Tuas, Singapore, while President Shanmugaratnam conducts a state visit to Sweden.Moves Bristol-Myers Squibb
-
FDA StructuralAbbott Laboratories faces an FDA recall classification of its sensors, while Ken Fisher and Donald Trump engage in stock transactions.Moves Bristol-Myers Squibb
-
Nvidia StructuralResearchers from Intel, Google, and others confirmed a new concept using Nvidia GPUs in an OCP demonstration.Moves Bristol-Myers Squibb
-
Halozyme Therapeutics StructuralCorcept Therapeutics and Halozyme Therapeutics are identified as top holdings in specific U.S. small-cap ETFs.Moves Bristol-Myers Squibb
-
Medicare StructuralAmy Gleason leads the CMS Health Tech Ecosystem program.Moves Bristol-Myers Squibb
-
Novartis OperationalSean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Moves Bristol-Myers Squibb
Connections
The 40 strongest of 530, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AstraZeneca Transactional
The two pharmaceutical companies are engaged in high-stakes merger talks regarding a potential combined entity valued at approximately $400 billion.
-
Karuna Therapeutics Structural
Bristol-Myers Squibb acquired Karuna Therapeutics, establishing Karuna as a subsidiary.
-
SEC Structural
Bristol-Myers Squibb is subject to mandatory financial disclosure and regulatory oversight by the SEC.
-
Cantor Fitzgerald Operational
Cantor Fitzgerald monitors Bristol-Myers Squibb's clinical and financial data to inform investment ratings and market coverage.
-
BioNTech Structural
Bristol-Myers Squibb and BioNTech maintain a strategic partnership for the co-development and co-commercialization of the bispecific antibody BNT327.
-
Securities and Exchange Commission Structural
Bristol-Myers Squibb operates under formal regulatory oversight by the SEC, requiring mandatory financial filings.
-
AbbVie Operational
The companies are active pharmaceutical peers engaged in market competition and collaborative research initiatives.
-
Houston Structural
Bristol-Myers Squibb is establishing a major manufacturing campus in the Houston region.
Show all 40 connections
-
FDA Structural
The FDA formally regulates and grants market approval for Bristol-Myers Squibb's pharmaceutical products.
-
Nvidia Structural
A strategic partnership exists where A provides critical AI infrastructure (DGX SuperPOD, GPUs) that B utilizes to accelerate its drug discovery platform.
-
Celgene Structural
Bristol-Myers Squibb has acquired Celgene, leading to ongoing integration and associated litigation risk.
-
Halozyme Therapeutics Structural
Halozyme licensed its ENHANZE drug delivery technology to Bristol-Myers Squibb, establishing a technology supply dependency.
-
Medicare Structural
Medicare regulates Bristol-Myers Squibb's market access, pricing, and revenue through formal price control schemes and challenges.
-
Joe Bolger Structural
Joe Bolger is employed as a sales representative by Bristol-Myers Squibb.
-
Singapore Structural
BMS has established Singapore as its Pan Asia Cluster hub for operational functions.
-
Sheila Gujrathi Structural
Sheila Gujrathi previously served as a Vice President at Bristol-Myers Squibb.
-
New York Stock Exchange Structural
Bristol-Myers Squibb is listed on the New York Stock Exchange.
-
Evotec Operational
Evotec and Bristol-Myers Squibb maintain a strategic partnership focused on drug discovery, including molecular glue degraders and targeted protein degradation.
-
Texas Structural
BMS is expanding domestic manufacturing in Texas, supported by state funding and program support.
-
Mayada Structural
Bristol-Myers Squibb appointed Mayada to the role of General Manager.
-
Pfizer Operational
Pfizer and Bristol-Myers Squibb maintain an operational relationship characterized by both active market competition and formal product collaboration, notably regarding Eliquis.
-
Ben Hickey Structural
BMS is the parent company of RayzeBio, where Ben Hickey serves as President.
-
Novartis Operational
The two companies are direct, high-stakes competitors in the advanced clinical development of treatments for myeloma.
-
HUMIRA Structural
The company utilizes the product as a core part of its therapeutic offerings, which are currently facing market pressures from biosimilar competition.
-
Novo Nordisk Operational
The two companies are direct competitors operating within the broader healthcare sector.
-
Norges Bank Transactional
Norges Bank has repeatedly purchased new investment positions in Bristol-Myers Squibb shares.
-
Bank of America Operational
Bank of America actively influences Bristol-Myers Squibb's market valuation by issuing financial ratings and target price adjustments.
-
Cytokinetics Operational
The companies are direct competitors in the development and market presence of medicines for Hypertrophic Cardiomyopathy (HCM).
-
Johnson & Johnson Operational
The two companies are direct competitors vying for market share and innovation in the global biopharma and healthcare sectors.
-
Merck Operational
Both companies actively compete in the oncology sector and are frequently included in the SCHD ETF.
-
CMS Structural
CMS formally negotiates drug prices for Bristol-Myers Squibb, establishing a market access dependency.
-
Andrew Whitehead Structural
Andrew Whitehead holds the executive role of Vice President at Bristol-Myers Squibb.
-
Kardigan Transactional
Kardigan licensed a lead drug from Bristol-Myers Squibb.
-
Luisa Salter-Cid Transactional
Luisa Salter-Cid held the specific professional role of VP and Head of Immunology at Bristol-Myers Squibb.
-
Hengrui Transactional
The relationship is characterized by the announcement and execution of significant business deals concerning drug program development.
-
Leerink partners Operational
Leerink Partners provides market commentary and rating changes regarding companies in the pharmaceutical sector.
-
Dementia Structural
Bristol-Myers Squibb provides funding to Dementia to support clinical studies and research development.
-
Gilead Sciences Operational
The two companies are major biopharma competitors, actively vying for market share in specialized therapeutic areas like TIGIT-blocking.
-
European Society of Cardiology Operational
Bristol-Myers Squibb actively presents clinical and real-world data at the European Society of Cardiology congresses.
-
Vanguard Structural
Vanguard's funds maintain Bristol-Myers Squibb as one of their top five holdings.
History
Events by the month they beganOctober 2026
10 events- Bristol-Myers Squibb and Özlem Türeci presented late-stage oncology pipeline data and joint development activity in Mainz.
- Companies are pouring billions into protein degraders, a drug class that has received FDA approval and is being discussed by ASCO.
- UICC was registered in Geneva on October 1, 2026, involving Bristol-Myers Squibb.
- Canadian investors can access U.S. companies, including Bristol-Myers Squibb, via Canadian Deposit Receipts (CDRs).
- Texas AG Ken Paxton sued pharmaceutical companies Sanofi and Bristol-Myers Squibb over alleged drug concealment.
- Bristol-Myers Squibb and Novo Nordisk are noted as competitors in the healthcare sector.
- Major pharmaceutical companies are competing for investment capital.
- GSK and Bristol-Myers Squibb are funding research and development for dementia treatments.
- Companies across various sectors are actively seeking advanced solutions to enhance their cyber resilience capabilities.
- Jay Korada held senior analytics roles at both AbbVie and Bristol-Myers Squibb.
September 2026
17 events- Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.
- FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- Market competition observed in the large-cap healthcare sector involving Bristol-Myers Squibb and Orion OYJ.
- MarketBeat reported consensus analyst targets and compared financial health for Bristol-Myers Squibb and Shionogi & Co., Ltd.
- Bristol-Myers Squibb holds exclusive commercial rights in Japan after the FDA accepted Zenas's Biologics License Application.
- Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.
- AbbVie, AstraZeneca, and Bristol-Myers Squibb collaborated on the AISB Bind AI initiative.
- ENCell secured a U.S. patent involving the work of the Samsung Life Public Welfare Foundation, which is connected to Bristol-Myers Squibb.
- The Israel National Biotech Innovation Center (INBI) is established as a national center of excellence and a founding partner to various academic and corporate institutions.
- Robert Plenge holds various appointments, including Chief Research Officer at Bristol-Myers Squibb, and serves on the boards of BioMarin Pharmaceutical and the PhRMA Foundation.
- Manufacturers Life Insurance Company reduced its share position in Bristol-Myers Squibb.
- Insider sale disclosed in SEC filing involving Bristol-Myers Squibb.
- Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.
- Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.
- Pfizer is based in New York and Bristol-Myers Squibb is based in Princeton, New Jersey.
August 2026
25 events- CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.
- The FDA approved Zenbexus oral therapy for multiple myeloma, coinciding with disclosures regarding insider buying and selling transactions.
- Major healthcare companies like BMS, J&J, and EL are facing market pressures, including biosimilar erosion, while maintaining strong sector positions.
- Bristol-Myers Squibb announced a $2.3 billion investment in Houston, and Brownsville is slated to receive a new oil refinery.
- Leerink and Stifel analysts commented on efficacy data following the separation of Myqorzo from the Camzyos market.
- Joe Bolger is employed by Bristol-Myers Squibb as a sales representative.
- Negotiated prices are impacting market access and revenue for major pharmaceutical companies like Pfizer, UCB, Bristol-Myers Squibb, and Novartis.
- Corporate news includes the acquisition of Vidya Therapeutics by Processa Pharmaceuticals, the $7.2 billion acquisition of Receptos by Celgene, and updates regarding Gujrathi's professional history with BMS.
- RayzeBio, acquired by Bristol-Myers Squibb, plans a $173 million investment and new facility in Boone County, Indiana.
- Analysts raised price targets on Bristol-Myers Squibb shares.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Bristol-Myers Squibb filed Form 13F with the Securities and Exchange Commission on August 25, 2026.
- Roche, Novo Nordisk, and Bristol-Myers Squibb are evaluating new drug candidates for Parkinson's, ATTR amyloidosis, and Alzheimer's diseases.
- Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.
- Bristol-Myers Squibb and AstraZeneca announced a collaboration on advanced cancer drug development.
- Norges Bank bought shares in Bristol-Myers Squibb (BMY), while TD Cowen and Raymond James Financial started coverage, and Truist Financial reiterated buy ratings.
- Bristol-Myers Squibb and others demand policy changes regarding labor and wages from the central government.
- Vanguard ETF holds major positions in companies including Bristol-Myers Squibb, General Motors, AT&T, Salesforce, EOG Resources, Intuit, and Pfizer.
- Bristol-Myers Squibb is establishing a new manufacturing campus in the Houston region, supported by a TEF grant and favorable business climate.
- A pilot program involving pharmacies in Alabama and Missouri is underway, with Bristol-Myers Squibb personnel involved.
- Nvidia, Eli Lilly, Bristol-Myers Squibb, and Hoffmann-La Roche announced a partnership to build a hybrid-cloud AI factory and powerful AI infrastructure.
- AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.
- Arcus Biosciences established a collaboration with Bristol-Myers Squibb and discussed study plans with the FDA on August 1, 2026.
- Halozyme tracks patient usage of OCREVUS ZUNOVO and monitors Opdivo Qvantig sales and conversion rates.
- Talks are underway regarding a potential $400bn mega-merger involving Pfizer, AstraZeneca, and Bristol-Myers Squibb.
Show 1 earlier month
June 2026
8 events- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- Bristol-Myers Squibb's price target was cut by Cantor Fitzgerald following clinical setbacks.
- Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.
- Bristol Myers Squibb filed with the SEC on May 28, 2026, regarding increased institutional ownership and share purchases.
- Pfizer is jointly marketing the drug Eliquis.
- Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.
- The FDA received information on June 27, 2025, regarding regulatory approval to streamline patient monitoring for a product involving Bristol-Myers Squibb.
- Bristol-Myers Squibb has taken ownership of Celgene's drug.